292 related articles for article (PubMed ID: 16568439)
1. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
Dingli D; Schwager SM; Mesa RA; Li CY; Dewald GW; Tefferi A
Cancer; 2006 May; 106(9):1985-9. PubMed ID: 16568439
[TBL] [Abstract][Full Text] [Related]
2. Conventional cytogenetics in myelofibrosis: literature review and discussion.
Hussein K; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119
[TBL] [Abstract][Full Text] [Related]
3. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.
Tefferi A; Dingli D; Li CY; Dewald GW
Cancer; 2005 Oct; 104(8):1656-60. PubMed ID: 16104040
[TBL] [Abstract][Full Text] [Related]
4. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
Hussein K; Huang J; Lasho T; Pardanani A; Mesa RA; Williamson CM; Ketterling RP; Hanson CA; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 Apr; 82(4):255-9. PubMed ID: 19215287
[TBL] [Abstract][Full Text] [Related]
5. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
Hidaka T; Shide K; Shimoda H; Kameda T; Toyama K; Katayose K; Kubuki Y; Nagata K; Takenaka K; Akashi K; Okamura T; Niho Y; Mizoguchi H; Omine M; Ozawa K; Harada M; Shimoda K
Eur J Haematol; 2009 Oct; 83(4):328-33. PubMed ID: 19549278
[TBL] [Abstract][Full Text] [Related]
6. Transplant decision-making strategies in the myeloproliferative disorders.
Fruchtman SM
Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.
Gangat N; Tefferi A; Thanarajasingam G; Patnaik M; Schwager S; Ketterling R; Wolanskyj AP
Eur J Haematol; 2009 Jul; 83(1):17-21. PubMed ID: 19236446
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia.
Strasser-Weippl K; Steurer M; Kees M; Augustin F; Tzankov A; Dirnhofer S; Fiegl M; Simonitsch-Klupp I; Gisslinger H; Zojer N; Ludwig H
Cancer; 2006 Dec; 107(12):2801-6. PubMed ID: 17103442
[TBL] [Abstract][Full Text] [Related]
9. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
Abdulkarim K; Ridell B; Johansson P; Kutti J; Safai-Kutti S; Andréasson B
Eur J Haematol; 2011 Feb; 86(2):148-55. PubMed ID: 21059102
[TBL] [Abstract][Full Text] [Related]
10. [Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera].
Roche-Lestienne C; Andrieux J
Pathol Biol (Paris); 2007 Feb; 55(1):49-55. PubMed ID: 16901657
[TBL] [Abstract][Full Text] [Related]
11. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
Kvasnicka HM; Thiele J
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
[TBL] [Abstract][Full Text] [Related]
12. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.
Dingli D; Schwager SM; Mesa RA; Li CY; Tefferi A
Cancer; 2006 Feb; 106(3):623-30. PubMed ID: 16369987
[TBL] [Abstract][Full Text] [Related]
13. Prognostic parameters in myeloid metaplasia: agnogenic versus postpolycythemic.
Meytes D; Katz D; Ramot B
Isr J Med Sci; 1976 Jun; 12(6):534-42. PubMed ID: 955869
[TBL] [Abstract][Full Text] [Related]
14. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.
Passamonti F; Malabarba L; Orlandi E; Baratè C; Canevari A; Brusamolino E; Bonfichi M; Arcaini L; Caberlon S; Pascutto C; Lazzarino M
Haematologica; 2003 Jan; 88(1):13-8. PubMed ID: 12551821
[TBL] [Abstract][Full Text] [Related]
15. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
[TBL] [Abstract][Full Text] [Related]
16. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy.
Tefferi A; Strand JJ; Lasho TL; Elliott MA; Li CY; Mesa RA; Dewald GW
Cancer; 2006 Apr; 106(8):1739-43. PubMed ID: 16532437
[TBL] [Abstract][Full Text] [Related]
17. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
[TBL] [Abstract][Full Text] [Related]
18. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia.
Hsiao HH; Ito Y; Sashida G; Ohyashiki JH; Ohyashiki K
Leuk Res; 2005 Nov; 29(11):1247-52. PubMed ID: 16164981
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients.
Djordjevic V; Dencic-Fekete M; Jovanovic J; Bizic S; Jankovic G; Bogdanovic A; Cemerikic-Martinovic V; Gotic M
Cancer Genet Cytogenet; 2007 Feb; 173(1):57-62. PubMed ID: 17284371
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia.
Reilly JT
Semin Oncol; 2005 Aug; 32(4):359-64. PubMed ID: 16202681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]